Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 111

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 111
---

    Net loss 
    $(15,022,027) 
    $(15,423,471)
  
    Other comprehensive income: 

    Reclassification adjustment for interest earned on marketable securities included in net loss 
     -  
     (430,993)
  
    Change in unrealized gain on marketable securities 
     -  
     334,559 
  
    Comprehensive loss 
    $(15,022,027) 
    $(15,519,905)

See
accompanying notes to the consolidated financial statements and report of independent registered public accounting firm

F-4

INDAPTUS
THERAPEUTICS, INC.

Consolidated
Statements of Stockholders’ Equity

    Shares  
    Amount  
    Capital  
    deficit  
    Income  
    Total 

    Common stock  
    Additional paid in  
    Accumulated  
    Accumulated Other Comprehensive  

    Shares  
    Amount  
    Capital  
    deficit  
    Income  
    Total 

    Balance, January 1, 2023 
     8,401,047  
    $84,011  
    $54,443,705  
    $(29,993,685) 
    $96,434  
    $24,630,465 
  
    Stock-based compensation 
     -  
     -  
     2,965,938  
     -  
     -  
     2,965,938 
  
    Reclassification adjustment for interest earned on marketable securities included in net loss 
     -  
     -  
     -  
     -  
     (430,993) 
     (430,993)
  
    Change in unrealized gain on marketable securities 
     -  
     -  
     -  
     -  
     334,559  
     334,559 
  
    Net loss 
     -  
     -  
     -  
     (15,423,471) 
     -  
     (15,423,471)
  
    Balance, December 31, 2023 
     8,401,047  
    $84,011  
    $57,409,643  
    $(45,417,156)